沃森生物(300142.SZ):簽署13價肺炎球菌多糖結合疫苗海外銷售協議
格隆匯 4 月 27日丨沃森生物(300142.SZ)公佈,公司控股子公司玉溪沃森生物技術有限公司(“玉溪沃森”)於近日與摩洛哥MarocVax Sarl公司 (“MarocVax”)達成合作,雙方就玉溪沃森生產的13價肺炎球菌多糖結合疫苗(“13價肺炎結合疫苗”)在摩洛哥的成品進口、分銷、銷售及其原液供應合作業務簽訂了獨家經銷協議。
同時,玉溪沃森與MarocVax還簽署了13價肺炎結合疫苗原液分裝技術轉移協議,將部分技術轉移給MarocVax在摩洛哥使用,MarocVax不得許可他人在摩洛哥之外使用該技術,與技術有關的所有知識產權仍歸玉溪沃森所有。技術轉移內容包括半成品和成品的質量檢驗方法、文件及方法學驗證等。
最低銷售量:2021年13價肺炎結合疫苗在摩洛哥的銷售量預測為200萬劑。當完成技術轉移後,MarocVax將從玉溪沃森採購半成品原液,採購的原液量至少等同於200萬劑疫苗成品。MarocVax承諾從第2個商業年開始的每個商業年度至少達到80%的銷售量預測。
如果自產品註冊成功後的任意3個連續商業年度,MarocVax均未達到至少50%的約定最低採購量和/或銷售金額(“連續未達到”),玉溪沃森可在6個月前書面通知終止本協議。
此次13價肺炎結合疫苗獨家經銷協議的簽署,標誌着公司13價肺炎結合疫苗國際銷售邁出了第一步,契合公司全面國際化戰略,對公司13價肺炎結合疫苗進軍國際市場,進一步強化公司品牌將產生積極影響,同時使得公司的產品增加納入摩洛哥國家免疫規劃的可能性。如13價肺炎結合疫苗後續在摩洛哥實現銷售後將對公司當年及未來經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.